Welcome to our dedicated page for Precision Optics SEC filings (Ticker: POCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Precision Optics Corporation, Inc. (NASDAQ: POCI), a vertically integrated optics company serving healthcare and defense/aerospace markets. Although specific filings are not listed here, POCI’s reports on EDGAR typically include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with other required disclosures.
Through these filings, Precision Optics presents detailed information about its business, which centers on proprietary micro-optics, 3D imaging and digital imaging technologies. The company describes how it supports medical device and defense/aerospace customers from new product concept through mass manufacture, including engineering and production revenue streams, facility expansions and risk factors related to demand, supply chains and economic conditions.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain key sections of lengthy filings in plain language. For example, users can quickly see how management discusses trends in engineering versus production revenue, how non-GAAP measures such as Adjusted EBITDA are reconciled to GAAP results, and how the company characterizes its exposure to healthcare and defense/aerospace markets.
Investors can use this page to monitor new 10-K and 10-Q filings as they are posted to EDGAR in real time, as well as any 8-K current reports that may describe material events such as new development agreements, facility moves or changes in capital structure. Where applicable, insider transaction reports on Form 4 and proxy statements on Schedule 14A can also be reviewed to understand equity compensation practices and ownership changes.
By combining official SEC documents for POCI with AI-generated insights, this page helps users navigate complex regulatory filings and focus on the disclosures most relevant to Precision Optics’ optical instrument business.
Precision Optics Corporation reported sharply higher sales but continued losses for the quarter and six months ended December 31, 2025. Quarterly revenue rose to $7.37 million from $4.53 million, and six-month revenue reached $14.05 million versus $8.72 million, driven mainly by strong Systems Manufacturing growth.
Profitability deteriorated significantly. Gross margin fell to 2.8% for the quarter and 8.2% year-to-date, with gross profit of only $0.20 million in the quarter. The company posted a quarterly net loss of $1.78 million and a six-month net loss of $3.42 million, larger than the prior-year losses.
Liquidity is tight. Cash and cash equivalents were $0.88 million at December 31, 2025, down from $1.77 million at June 30, 2025. Management states existing cash is insufficient to fund planned operations for at least one year from issuance of the statements and concludes there is substantial doubt about the company’s ability to continue as a going concern.
Precision Optics Corporation, Inc. has amended its definitive proxy statement only to update the record date for its 2025 Annual Meeting of Shareholders to January 29, 2026. The annual meeting will be held on March 19, 2026 at the company’s Littleton, MA headquarters.
Shareholders will vote on three key items: electing five directors to one-year terms, approving on an advisory basis executive compensation for the year ended June 30, 2025, and ratifying Stowe & Degon LLC as independent registered public accounting firm for the year ending June 30, 2026. The proxy details board composition, committee structures, director and executive pay (including recent option grants), major shareholders, equity incentive plans, and governance policies such as a clawback policy, insider trading and hedging restrictions, and the process for shareholder proposals for the 2026 meeting.
Precision Optics Corporation, Inc. has scheduled its 2025 Annual Meeting for March 19, 2026 at its Littleton, MA headquarters. Shareholders of record on January 28, 2026 may vote.
Investors will vote on electing five directors, approving on an advisory basis executive compensation, and ratifying Stowe & Degon LLC as independent registered public accounting firm for the year ending June 30, 2026. The Board recommends voting FOR all three proposals.
The proxy outlines a five‑member board with a majority of independent directors and active Audit and Compensation Committees. For fiscal 2025, CEO Joseph N. Forkey received total compensation of $1,106,559, including salary, stock, and options, while total net loss was
Precision Optics Corporation, Inc. (POCI) reported a new equity award to a director on a Form 4. The filing shows a grant of stock options to purchase 30,000 shares of common stock at an exercise price of $4.33 per share on 11/17/2025, reported as an acquisition of derivative securities held directly.
The options expire on 11/17/2035 and were granted under the company’s 2022 Equity Incentive Plan. They vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, conditioned on the director’s continuous service with the company through each applicable vesting date.
Precision Optics Corporation, Inc. (POCI) reported that one of its directors received a grant of 30,000 stock options on 11/17/2025. The options have an exercise price of $4.33 per share and are exercisable for an equal number of shares of common stock, with an expiration date of 11/17/2035. They were granted under the company’s 2022 Equity Incentive Plan.
The options vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, as long as the director remains in continuous employment with Precision Optics through each vesting date. Following this grant, the director holds 30,000 derivative securities directly.
Precision Optics Corporation, Inc. (POCI) reported an insider equity award for a director. The filing shows a grant of stock options, which are rights to buy common stock in the future at a fixed price.
The director received 30,000 stock options with an exercise price of $4.33 per share, becoming exercisable over time. According to the filing, these options vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, as long as the director remains in continuous employment with the company through each vesting date. The options were granted under the company’s 2022 Equity Incentive Plan and are scheduled to expire on November 17, 2035.
Precision Optics Corporation, Inc. (POCI) reported an equity award to one of its directors. On 11/17/2025, the director received stock options giving the right to buy 30,000 shares of POCI common stock at an exercise price of $4.33 per share. These options expire on 11/17/2035 and were granted under the company’s 2022 Equity Incentive Plan.
The options vest in four equal installments on December 30, 2025, March 30, 2026, June 29, 2026, and September 29, 2026, as long as the director remains continuously employed by the company through each applicable vesting date.
Precision Optics (POCI) filed its quarterly results for the period ended September 30, 2025. Revenue rose to $6.68 million from $4.20 million a year ago, driven by a near tripling in Systems Manufacturing sales as programs scaled. Despite higher sales, profitability weakened: gross margin fell to 14.2% from 26.6%, and net loss widened to $1.64 million (basic and diluted loss per share $0.21), matching the prior-year per‑share loss on a higher share count.
Engineering Design Services revenue decreased as work transitioned to production, Micro Optics was soft on delayed defense orders, and Ross Optical grew modestly. Operating cash flow was a small positive at $78,227, while cash ended at $1.39 million. Accounts payable and contract liabilities increased alongside activity. The company obtained lender waivers of its debt service coverage covenant for fiscal 2024 and 2025; as of September 30, 2025, it was not in compliance with the 1.20x quarterly test, and future advances under the revolver depend on meeting that covenant. Management states current plans, potential credit availability, and access to capital markets are expected to support at least 12 months of operations.
Precision Optics Corporation (POCI) disclosed a Form 4 showing an inducement stock option grant to its Chief Operating Officer. On October 1, 2025, the executive received options to purchase 60,000 shares of common stock at an exercise price of $4.34 per share.
The option vests in three equal annual installments beginning October 1, 2026, and expires on October 1, 2035. Following the grant, the reporting person beneficially owns 60,000 derivative securities, held directly.
Precision Optics Corporation (POCI)no securities are beneficially owned as of 10/01/2025.
The filing is marked as Form filed by One Reporting Person and was executed by Joseph N. Forkey as attorney-in-fact, with an attached Exhibit 24 – Power of Attorney.